You searched for "AMN"
The bionic eye – behind the headlines
Multiple visual prosthetic projects and other vision regeneration initiatives being tested in preclinical and clinical development worldwide illustrate continuing progress and opportunities in addressing profound blindness from hereditary retinal diseases and other causes (Table 1). Three implantable bionic vision systems...What’s new in wet AMD papers?
1 December 2016
| Rod McNeil
|
EYE - Vitreo-Retinal
Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...
My top five: Innovative approaches to dry AMD
2 February 2024
| Nikhil Sharma
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
My Top Five: Innovative approaches to dry AMD
2 February 2024
| Nikhil Sharma
|
EYE - General
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
Age-related macular degeneration
1 December 2015
| Nana Theodorou
|
EYE - Vitreo-Retinal
This review article offers an up to date review of the genetic and environmental risk factors associated with aetiology surrounding age-related macular degeneration (AMD). The article briefly describes the typical clinical presentation relating to early and late stages of the...
Four year outcomes of macular degeneration treated with ranibizumab
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
Pegcetacoplan: A breakthrough treatment for dry age-related macular degeneration?
Age-related macular degeneration (AMD) is a degenerative condition affecting the macula, the part of the retina responsible for central vision. It is characterised by the presence of drusen and retinal pigment epithelium (RPE) abnormalities in the absence of other macular...
Features of AMD treatment non-responders
1 October 2019
| Jonathan Chan
|
EYE - Vitreo-Retinal
This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...
Characteristics of Charles Bonnet syndrome in patients with neovascular AMD
7 April 2021
| Ed Rule
|
EYE - Vitreo-Retinal
|
Age-related macular degeneration, Charles Bonnet syndrome, Low vision, Negative outcome, Visual hallucinations
This retrospective cross-sectional study aimed to characterise various aspects of Charles Bonnet syndrome hallucinations among patients with neovascular age-related macular degeneration (AMD). Five hundred and ten consecutive patients were asked a screening question to determine if they had ever suffered...
Changes in drusen and retinal layer volumes prior to CNV development
7 April 2021
| Ed Rule
|
EYE - Vitreo-Retinal
|
Age-related macular degeneration, Choroidal neovascularisation type, Drusen load, Imaging biomarkers, Retinal layer volumes
This retrospective longitudinal study looked at patients with wet age-related macular degeneration (AMD) in one eye who subsequently developed wet AMD in the fellow eye. The aim was to discover whether drusen characteristics or volumes of retinal layers correlate with...
New partnership to prevent unnecessary sight loss
13 December 2022
Sight loss charity the Macular Society has announced a new partnership with OcuPlan, a service designed to give patients with long-term eye conditions such as macular disease affordable access to specialist care to prevent unnecessary sight loss.
It’s not all about ARED - Time for a pragmatic approach to nutrition for eye health?
1 April 2016
| Christine Purslow (Prof)
|
EYE - Cornea
Advances in treatment for retinal diseases involving neovascularisation have undoubtedly changed the future of eye care across the UK for the better, but also created great challenges for service delivery in ophthalmology, particularly within the NHS. Some statistics are starting...
